Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency
|ClinicalTrials.gov Identifier: NCT01339741|
Recruitment Status : Unknown
Verified April 2011 by Chulalongkorn University.
Recruitment status was: Recruiting
First Posted : April 21, 2011
Last Update Posted : April 21, 2011
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis Vulgaris Vitamin D Deficiency||Dietary Supplement: Vitamin D3 Drug: Placebo||Not Applicable|
While psoriasis is not a lethal disease, the disease itself can impact patients' quality of life. Nowadays there are several researches on vitamin D functions. Recently review article of vitamin D deficiency by Holick MF., stated that vitamin D can play a role in decreasing the risk of osteoporosis and other chronic diseases such as malignancy, autoimmune disease, infectious disease, cardiovascular disease, and psoriasis. Moreover, vitamin D effects on keratinocyte by decreasing abnormal cell proliferation, differentiation, apoptosis and controlling immunological process via the suppression of T-cell activation, regulation of cytokine secretion patterns, induction of regulatory T-cell, modulation of T-cell proliferation and interference with T-cell apoptosis.
Thus, our objective is to look for other alternative treatment, which may have less side effects and acceptable clinical outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||The Efficacy of Vitamin D3 for the Treatment of Chronic Plaque Type Psoriatic Patients With Vitamin D Deficiency and Insufficiency: a Randomized Controlled Trial|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||February 2012|
|Estimated Study Completion Date :||February 2012|
|Active Comparator: Vitamin D||
Dietary Supplement: Vitamin D3
Vitamin D3, oral supplement, 12 weeks
|Placebo Comparator: Placebo||
Placebo, oral route, 12 weeks
- Psoriasis Area and Severity Index (PASI Score) [ Time Frame: 12 weeks ]Normal vitamin D level after replacement correlate with improved clinical outcome (PASI Score) of psoriasis vulgaris.
- Dermatologic Life Qualify Index (DLQI) [ Time Frame: 12 weeks ]Normal vitamin D level after replacement correlates with better DLQI.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01339741
|Contact: Chotinij Lertphanichkul, M.D.||662-256-4000 ext email@example.com|
|Contact: Marisa Pongprutthipan, M.D.||662-256-4000 ext firstname.lastname@example.org|
|Chotinij Lertphanichkul, M.D.||Recruiting|
|Patumwan, Bangkok, Thailand, 10330|
|Contact: Chotinij Lertphanichkul, M.D. 662-256-4000 ext 4253 email@example.com|
|Contact: Marisa Pongprutthipan, M.D. 662-256-4000 ext 4253 firstname.lastname@example.org|
|Principal Investigator: Chotinij Lertphanichkul, M.D.|
|Principal Investigator:||Chotinij Lertphanichkul, M.D.||Chulalongkorn University|